258 related articles for article (PubMed ID: 23296792)
1. Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease.
Negri AL
Int Urol Nephrol; 2014 Jan; 46(1):9-17. PubMed ID: 23296792
[TBL] [Abstract][Full Text] [Related]
2. Update on fibroblast growth factor 23 in chronic kidney disease.
Wolf M
Kidney Int; 2012 Oct; 82(7):737-47. PubMed ID: 22622492
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.
Hu P; Xuan Q; Hu B; Lu L; Wang J; Qin YH
Int J Biol Sci; 2012; 8(5):663-71. PubMed ID: 22606047
[TBL] [Abstract][Full Text] [Related]
4. [New markers of cardio-renal links in chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
[TBL] [Abstract][Full Text] [Related]
5. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
[TBL] [Abstract][Full Text] [Related]
6. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
[TBL] [Abstract][Full Text] [Related]
7. Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.
Edmonston D; Wojdyla D; Mehta R; Cai X; Lora C; Cohen D; Townsend RR; He J; Go AS; Kusek J; Weir MR; Isakova T; Pencina M; Wolf M;
Am J Kidney Dis; 2019 Dec; 74(6):771-781. PubMed ID: 31445926
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation.
Eser B; Yayar O; Buyukbakkal M; Erdogan B; Ercan Z; Merhametsiz O; Haspulat A; Oğuz EG; Dogan İ; Canbakan B; Ayli MD
Nefrologia; 2015; 35(5):465-72. PubMed ID: 26394828
[TBL] [Abstract][Full Text] [Related]
9. FGF23: a mature renal and cardiovascular risk factor?
Zoccali C; Yilmaz MI; Mallamaci F
Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
[TBL] [Abstract][Full Text] [Related]
10. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
11. Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014.
Wolf M
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1875-85. PubMed ID: 26350436
[TBL] [Abstract][Full Text] [Related]
12. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
Vogt I; Haffner D; Leifheit-Nestler M
Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
[TBL] [Abstract][Full Text] [Related]
13. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.
Tanaka H; Hamano T; Fujii N; Tomida K; Matsui I; Mikami S; Nagasawa Y; Ito T; Moriyama T; Horio M; Imai E; Isaka Y; Rakugi H
Bone; 2009 Nov; 45(5):949-55. PubMed ID: 19631779
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
[TBL] [Abstract][Full Text] [Related]
15. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5.
Alderson HV; Ritchie JP; Middleton R; Larsson A; Larsson TE; Kalra PA
Nephrology (Carlton); 2016 Jul; 21(7):566-73. PubMed ID: 27334353
[TBL] [Abstract][Full Text] [Related]
16. FGF-23: the rise of a novel cardiovascular risk marker in CKD.
Heine GH; Seiler S; Fliser D
Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630
[TBL] [Abstract][Full Text] [Related]
17. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
Larsson T; Nisbeth U; Ljunggren O; Jüppner H; Jonsson KB
Kidney Int; 2003 Dec; 64(6):2272-9. PubMed ID: 14633152
[TBL] [Abstract][Full Text] [Related]
18. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.
Diniz H; Frazão JM
Nefrologia; 2013 Nov; 33(6):835-44. PubMed ID: 24158124
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).
Ix JH; Katz R; Kestenbaum BR; de Boer IH; Chonchol M; Mukamal KJ; Rifkin D; Siscovick DS; Sarnak MJ; Shlipak MG
J Am Coll Cardiol; 2012 Jul; 60(3):200-7. PubMed ID: 22703926
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.
Manghat P; Fraser WD; Wierzbicki AS; Fogelman I; Goldsmith DJ; Hampson G
Osteoporos Int; 2010 Nov; 21(11):1853-61. PubMed ID: 20012018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
